Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAC-CAR in Poor-Risk Classical Hodgkin Lymphoma
NCT06617286Phase 2Not yet recruiting
- Sponsor
- New York Medical College
- Start
- Dec 2026
- Primary completion
- Dec 2039
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD30 CAR T-cell in classical Hodgkin lymphoma (cHL), sponsored by New York Medical College. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
CD30 CAR T-cell
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT06617286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06617286.